Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia

NCT01702155 is registered in ClinicalTrials.gov with Delta-Fly Pharma, Inc. as lead sponsor.

NCT NCT01702155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01702155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia
Lead sponsor
Delta-Fly Pharma, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 10, 2012
Completion date
October 11, 2017
Enrollment
69 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, acute myeloid leukemia